KDR and ovarian cancer: LY3127804 and aflibercept combination has shown efficacy in mouse models.14 Furthermore, LY3127804 in combination with DC101, a murine anti-VEGFR2 antibody, had greater efficacy than LY3127804 monotherapy in multiple patient-derived xenograft models including models for non-small cell lung cancer (NSCLC) and ovarian cancer.14 We report the findings of the first-in-human, Phase 1, dose-escalation study JQBA, which assessed the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of LY3127804 in patients with advanced solid tumours.